Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

A 20-Year Journey from Axonal Injury to Neurodegenerative Diseases and the Prospect of Immunotherapy for Combating Alzheimer’s Disease

Michal Schwartz, Javier M. Peralta Ramos and Hila Ben-Yehuda
J Immunol January 15, 2020, 204 (2) 243-250; DOI: https://doi.org/10.4049/jimmunol.1900844
Michal Schwartz
*Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA 02142; and
†Department of Neurobiology, Weizmann Institute of Science, Rehovot 7610001, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Javier M. Peralta Ramos
†Department of Neurobiology, Weizmann Institute of Science, Rehovot 7610001, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hila Ben-Yehuda
†Department of Neurobiology, Weizmann Institute of Science, Rehovot 7610001, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The understanding of the dialogue between the brain and the immune system has undergone dramatic changes over the last two decades, with immense impact on the perception of neurodegenerative diseases, mental dysfunction, and many other brain pathologic conditions. Accumulated results have suggested that optimal function of the brain is dependent on support from the immune system, provided that this immune response is tightly controlled. Moreover, in contrast to the previous prevailing dogma, it is now widely accepted that circulating immune cells are needed for coping with brain pathologies and that their optimal effect is dependent on their type, location, and activity. In this perspective, we describe our own scientific journey, reviewing the milestones in attaining this understanding of the brain–immune axis integrated with numerous related studies by others. We then explain their significance in demonstrating the possibility of harnessing the immune system in a well-controlled manner for the treatment of neurodegenerative diseases.

Introduction

Alzheimer's disease (AD) was first identified in 1906 as a disease characterized by distinctive plaques of amyloid-β and Tau neurofibrillary tangles associated with cognitive and mental dysfunction. Since then, numerous attempts were made to reverse or, at least, to modify or attenuate this disease by targeting the accumulating proteins, with the aim of plaque elimination (1–6). Unfortunately, such attempts have largely failed (7, 8). Over the years, several other studies suggested that AD, like many other acute and chronic neurodegenerative diseases, is associated with local inflammation (9), and efforts were therefore made to reduce it by systemic administration of steroidal or nonsteroidal anti-inflammatory drugs. Such treatments also failed to affect disease progression (10), leaving the scientific community with the question of what had been missed in the understanding of the disease (7, 11–13).

Independent basic research studies carried out by our group and others over the years strived for a deep understanding of the physiological mechanisms that maintain the healthy brain and help repair it. Such mechanisms might be lost or are insufficient under disease conditions, but could be amenable to boosting. To this end, we focused on the potential role of the immune system. When we embarked on this quest 20 years ago, even the possibility that immune cells might not be harmful to the brain and, needless to say, the suggestion that they could be beneficial was considered almost heretical.

Our journey was initiated by a simple assumption that it is inconceivable that the CNS, which is so precious and indispensable, would lack the capacity to be assisted by immune cells for its repair, whereas almost every other tissue depends on such immune support. Since then, we introduced and substantiated the essential role of the blood-borne innate and adaptive immune cells in supporting the brain during normal homeostasis and their vital role in repair following injury or facing neurodegenerative conditions (14–28). Based on these works, together with numerous additional studies by others (29–42), a new paradigm has emerged, suggesting that tightly regulated brain–immune communication is a necessary component of life-long brain maintenance and is essential for brain repair. More recently, it was found that brain–immune cross-talk is impaired in aging (43–47) and in neurodegenerative diseases (23, 48–50), and thus a fundamental mechanism of maintenance and support might be lost (23, 51) that could be amenable to restoration by rejuvenating the immune system (50–53).

These findings do not negate the original definition of the brain as an immune-privileged organ (54); they refine the understanding of the brain as an organ that, rather than functioning under complete segregation, engages in a unique and tightly regulated relationship with the immune system (55, 56). In this perspective, we describe our own scientific journey alongside with numerous related studies by others, from the original notion of systemic immune cells as destructive to the brain to their current recognition as crucial (if well controlled) (Fig. 1). We further describe the change of perspective from viewing the brain’s borders as absolute barriers between the brain and the circulation, to the current understanding that these borders can also serve as permissive gates for the entry of “reparative” leukocytes, as sites from which immune cells can affect the brain (37, 43, 57, 58), and as sites that can function as a lymphatic system for the brain (40, 41, 59–62). Finally, we explain the rationale underlying the shift from attempts to mitigate AD using immunosuppression to our proposal of harnessing the immune system by immunotherapy for the treatment of AD (50, 51).

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Milestones (in colors) in the understanding of the communication between the brain and the immune system. The journey started with the common wisdom that the brain is isolated from the immune system (54). Initial studies (I and II) that began to undermine these assumptions highlighted the need for circulating immune cells (both monocyte-derived macrophages and T cells) for brain repair (14, 15, 78, 79), followed by (III) initiation of studies showing that circulating immune cells are needed to support healthy brain plasticity (17, 18, 37, 39). These were also followed by (IV) studies showing the pivotal role of monocyte-derived macrophages (83–90) and of T cells (91, 92) in chronic neurodegenerative diseases. The above studies led to intensive research (V) striving to identify the site of communication between the brain and the immune system (20, 22, 23, 43, 49, 59), which led to the most recent approach (VI) of immunotherapy, empowering the peripheral immune system to fight against AD and dementia and, potentially, against additional neurodegenerative diseases (50, 51). (Note that many additional references related to each of these milestones are cited in the text).

Peripheral immune cell involvement in recovery from acute CNS injury

Outside the CNS, inflammation is a physiological response that is essential for tissue repair and becomes pathological if not resolved in a timely manner. As part of such peripheral “physiological” inflammation, macrophages were found to be essential players for removing dead cells and cell debris, as well as for facilitating immune resolution and tissue repair (63, 64). It is a multistep reparative process that starts with immune activation and ends with local immune resolution (19, 20, 26, 65–68). It is still debatable whether the immune resolution involves the recruitment of an additional wave of macrophages with distinct activities or whether it involves a local conversion of a single population of myeloid cells from an inflammatory to a resolving phenotype (69).

The general view, with respect to the CNS, was that it should be fully protected from immune cell entry to ensure its proper homeostasis and function. Accordingly, the failure of the CNS to recover following acute injury was often attributed to local inflammation, assuming that such inflammation might reflect, at least in part, infiltration of inflammatory cells to the site of damage, a process that should be altogether prevented or blocked (70, 71). Researchers indiscriminately viewed CNS local inflammation as an obstacle to recovery (72, 73) and to cell renewal (74–76). Therefore, it was suggested that acute treatment with steroidal anti-inflammatory drugs following spinal cord injury would promote repair (71, 77). In an apparent contrast, in animal models of acute CNS injury, including optic nerve injury (14, 67, 78), spinal cord injury (15, 16, 19, 79–82), and brain ischemia (35), it was found by our team, and subsequently by others, that blood-borne macrophages and T cells can facilitate repair. In addition, as will be discussed below, monocyte-derived macrophages were also found by several independent studies to have a role in coping with chronic brain pathologic conditions (37, 39, 78, 79, 83–92).

Overall, reparative macrophages were shown to locally display multiple functions, including anti-inflammatory (19, 20, 79), scar degrading activities (93, 94), and the ability to support axonal growth (78).

Peripheral immune cells in CNS homeostasis

The finding that peripheral immune cells can facilitate neural tissue protection and repair following CNS injury highlighted the possibility that the peripheral immunity might have a role in supporting CNS homeostasis and functional plasticity. To address this, initial studies focused on the hippocampus, which is known to exhibit life-long neurogenesis (95, 96), a high functional plasticity in its normal day-to-day activity, and is involved in spatial learning and memory (97, 98). It was discovered that neurogenesis, as well as spatial learning and memory, are impaired in young immune-compromised animals, suggesting that systemic immune cells affect healthy brain plasticity (17, 18, 29–34, 36–39, 42, 99, 100). Over the years, independent studies have identified the meninges as sites through which the immune system can affect the healthy brain. For example, T cell–derived IL-4 was found to enhance cognitive function (37). In addition, meningeal IFN-γ–producing immune cells were found to support social behavior (39). Similarly, deficiency of IFN-γ signaling from middle age onward was found to be linked to cognitive impairment (43). Other studies have suggested that the peripheral immune system supports the ability to cope with mentally stressful conditions (101–103). Along the same lines, alterations in T cell number and function have been associated with some cases of autism spectrum disorders (104–107). Taken together, these results and others have encouraged studies striving for a better understanding of the relationship between the brain and circulating immune cells.

The choroid plexus as a gateway for peripheral immune cells to the CNS.

In searching for physiological sites of brain–immune communications under “sterile” acute injurious conditions, our team found that monocytes can attain access to the CNS through the leptomeninges adjacent to the lesion site and through the blood–cerebrospinal fluid barrier (BCSFB) at the choroid plexus (CP) (20, 22). Those cells that enter through the BCSFB contribute to the resolution of the inflammation within the site of pathology (20). Investigating the properties of the CP revealed that the trafficking of leukocytes through it is different from the invasion of pathological immune cells through the breached endothelium of the blood–brain barrier in diseases such as multiple sclerosis (108, 109). Thus, for example, following spinal cord injury the epithelial layer of the CP was found to be activated to express increased levels of leukocyte trafficking molecules such as CCL2, ICAM-1, and CXCL10 (22). This activity of the CP was found to be dependent on signals originating from the circulation, such as IFN-γ, and signals emerging from the brain parenchyma, via the cerebrospinal fluid, informing the CP that the brain is in distress (22). Of interest, effector memory T cells were found to populate the CP stroma and to secrete cytokines, such as IFN-γ, IL-4, and IL-10, which can modify the activity of the CP epithelium to express chemokines, cell-adhesion molecules, and growth factors (22, 48). Of note, it is not yet clear whether the cells that reside in the CP and orchestrate its activity for supporting leukocyte trafficking are the same cells that are found in the cerebrospinal fluid and the parenchyma. Over the years, the CP was found to function as a physiological gateway for immune surveillance (20, 43, 101), and a correlation was found between expression of trafficking molecules by the CP and the number of leukocytes in the cerebrospinal fluid (101). The fate of the CP following traumatic injury to the brain has not been studied. Nevertheless, under acute mental stress, the expression of leukocyte trafficking molecules by the CP was found to be affected (101). Taken together, these emerging studies have demonstrated that the meninges and the CP have multiple functions in brain homeostasis, neurogenesis, and repair (20, 37, 43, 49, 110–114).

Further studies are needed to fully describe the relationship between T cells that populate the CP, those that pass through the CP, and those that populate the meninges.

Neurodegenerative diseases and myeloid cells

Approximately 10 percent of the brain’s cells are myeloid immune cells, known as microglia (115–117). They were shown to have a distinct origin from that of macrophages and a slow rate of self-renewal (115). The microglia are maintained under tight regulation, which allows them to act as sentinels and to restore homeostasis following a mild to moderate deviation due to disturbance or damage; however, such a tight regulation restricts their ability to display a robust activity under a severe (118) or persistent pathologic condition, as in the case of chronic neurodegeneration (119). Among the factors controlling microglial activity are cell–cell interactions based on receptor/ligand pairs, such as CD200L-CD200R (120) and CX3CL1-CX3CR1 (121), and soluble factors, such as TGF-β (119, 122, 123).

The role and function of microglia in neurodegenerative diseases have not been fully elucidated. Genome-wide association studies have identified disease-associated risk factors in AD patients, many of which are immune-related genes expressed by microglia (124–127) and other immune cells (128–131). Among such risk factors is triggering receptor expressed on myeloid cells 2 (TREM2) (132–135).

Using single-cell RNA sequencing in a mouse model of AD driven by amyloid-β, a novel subset of disease-associated microglia was identified. These cells develop through a stepwise process in a TREM2-dependent fashion (124). Based on the unique RNA expression profile of these cells, it appears that they may demonstrate protective activity (124). Nevertheless, it is not clear why these activated microglia are not sufficient to mitigate the disease (118, 136). It is possible that their maturation occurs late in the disease course or that these cells are able to function only transiently and become exhausted or even destructive (137). Importantly, there is no consensus, even with respect to the role of TREM2 in microglial activity; however, several findings suggest that the role of TREM2 in microglia, positive or negative, is dependent on the stage of the disease (135, 138–143). Overall, the role of microglia in neurodegenerative conditions is still under study, and their function or dysfunction could differ among diseases and their subsets.

In addition to the resident microglia, as mentioned above, monocyte-derived macrophages are also recruited to the CNS under disease pathologic conditions. Although the function of these cells has not been fully elucidated, several studies have suggested that they play an important beneficial role in AD (23, 50, 51, 83, 85–89, 144–149). Moreover, boosting the number of monocyte-derived macrophages in different models of AD, using various immunological manipulations, was found to be beneficial in reducing the pathology and improving cognitive function (51, 146–148). These monocyte-derived macrophages were found to exhibit features associated with enhanced phagocytic activity, along with the expression of scavenger receptors and cytokines that either are not expressed by microglia or are not induced in a timely manner when needed (51, 87, 146–149). Notably, the recruitment of monocytes to the CNS was shown to be dependent on the chemokine receptor CCR2 (86). Many of the genetic AD risk factors are associated with immune activity, including factors affecting microglia and monocyte-derived macrophages. Yet, it is evident from several independent studies that in these diseases the myeloid cells within the brain are strongly affected by environmental and nutritional factors, including ω-3 fatty acids (150), curcuminoids (151), vitamin D (152), and resveratrol (153).

It should be noted that in the past, many published studies globally referred to all myeloid cells in the brain as “microglia” with no direct distinction between myeloid cell types, and thus the conclusions might not accurately reflect the specific function of each population.

Immunotherapy to combat AD and tauopathies.

The disappointing results in many clinical trials aimed at modifying AD by eradication of amyloid-β plaque (1–4), together with the unclear causal relationships between the levels of plaque load in the brain and cognitive loss (154–156), have argued for the presence of additional factors, which may be responsible for the cognitive impairment and thus should be targeted (11, 157–159). It is conceivable that adopting a strategy to enhance multiple mechanisms of repair would be more effective than a strategy that directly puts down a single destructive process.

In addition to the monocyte-derived macrophages, regulatory T cells are needed, as well, in restricting inflammatory conditions within the brain (23, 92). In apparent contrast, peripheral effector T cells were also found to be important players in neurodegenerative conditions (91, 160–163). Together, these studies suggest that different cell types are displaying distinct functions at the brain's borders and within the brain parenchyma; effector T cells activate the gateway to the brain and allow trafficking through it, whereas monocytes and regulatory T cells are functioning within the site of pathology. Altogether, these results support the notion that aging and exhaustion of the immune system could contribute to the onset and escalation of neurodegenerative diseases. The challenge is how to maintain a balanced response and to orchestrate the activities of all these cell types.

Studies addressing the fate of the CP in animal models of neurodegenerative pathologies, such as AD and amyotrophic lateral sclerosis, revealed that its function as a leukocyte gateway is impaired (23, 48, 49). Restoring the function of the CP could be achieved by different strategies of boosting the peripheral immune system, including transient reduction of systemic Foxp3+ regulatory T cells (23), blocking the PD-1/PD-L1 immune checkpoint pathway (50, 51, 164), or vaccination by CNS Ags (48).

Targeting the PD-1/PD-L1 inhibitory immune checkpoint pathway in the periphery revealed that it is possible to modify disease pathology in animal models driven by amyloidosis and tauopathy (50, 51). For a long-term effect in AD and dementia, an intermittent treatment was found to be sufficient, and thus the potential for adverse immunological effects is likely to be low. Such a treatment (Fig. 2) was shown to reduce brain inflammation, rescue neurons, and reduce brain pathology, although it is not directly targeting any specific disease hallmark. The effect was attributed, at least in part, to the enhanced homing of monocytes to the brain (50, 51), which can augment tissue repair by locally functioning as inflammation-resolving cells, and by expressing scavenger molecules (87, 89, 149). It remains to be determined whether and how resident microglia are affected by such an intervention. Temporarily reducing immunosuppressive mechanisms helps release effector T cell activity, and at the same time, maintains a sufficient number of anti-inflammatory cells in the periphery. Such a treatment approach initiates an immunological chain of events affecting the peripheral immune system as the primary target of the treatment to allow trafficking of inflammation-resolving cells to the sites of brain pathology, in which they play an essential role (23, 92, 165) (Fig. 2).

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Schematic representation illustrating the dynamics and the mechanism underlying the disease modification evoked by empowering the peripheral immune system by immune checkpoint blockade. The Abs (e.g., directed to PD-1 or PD-L1) that block inhibitory immune checkpoints reach circulating immune cells, lymphoid organs, and, potentially, the immune cells within the BCSFB’s stroma. The interaction between the Abs and their relevant receptors results in multiple subsequent changes in the peripheral immune system including increased levels of PD-1+ CD4+ effector memory T cells and increased availability of IFN-γ, which activates the choroid plexus epithelium to express leukocyte trafficking molecules. The enhanced ability of the CP to express these molecules supports recruitment of monocyte-derived macrophages and regulatory T cells to the brain. The monocyte-derived macrophages can directly, as well as indirectly, display multiple activities, including suppression of the inflammatory milieu of the brain via local production of IL-10, facilitating removal of amyloid-β oligomers and plaques by expressing unique scavenger receptors (e.g., MSR1). Such an immune modulation is followed by enhanced neuronal survival, rescue of synapses, and a more supportive environment for the functioning of the brain. Altogether, this multistep process leads to disease modification and cognitive improvement.

Several recent studies have suggested additional targets for immunotherapy, based on directly modulating microglia by increasing their phagocytic activity via inhibition of either CD22 (166) or CD33 (167) or by reducing the shedding of TREM2 (168).

Overall, it seems that because of the heterogeneity of AD and dementia conditions and the multiple detrimental factors (environmental and innate) contributing to the cognitive impairment and disease escalation, the targeting of a single factor (e.g., amyloid-β plaque burden, accumulation of aggregated Tau, or local neuroinflammation) is apparently not sufficient to modify such diseases. By empowering the peripheral immune system, it might be possible to overcome the difficulties of coordinately targeting multiple factors that contribute to disease escalation and cognitive impairment, which may differ between patients, and at different timepoints along the course of the disease (169). Immunotherapy, in general, could serve as a means to harness the immune system to fight this disease, independently of its primary etiology, either familial or sporadic and whether it is driven by amyloid-β, Tau, or both. Also, this therapeutic strategy might overcome the need to identify the key precipitating factor(s) leading to the initiation of the pathologic condition or additional factors whose modification is critical to arrest disease progression, or at least change its course. The fact that aging is the major risk factor of all sporadic neurodegenerative diseases supports the notion that rejuvenating the immune system could be a promising therapeutic approach.

On a personal note, the fact that 20 years ago no one would have dared to consider an option as immunotherapy for AD emphasizes how a basic scientific question can lead to a surprising mechanism-based approach (Fig. 1).

Disclosures

M.S. is an inventor of the intellectual property that forms the basis for development of PD-L1 immunotherapy for AD.

Acknowledgments

M.S. holds the Maurice and Ilse Katz Professorial Chair in Neuroimmunology.

Footnotes

  • This work was supported by Advanced European Research Council Grant 232835, Israel Science Foundation (ISF) Research Grant 991/16, and ISF Legacy Heritage Biomedical Science Partnership Research Grant 1354/15. We thank the Adelis and Thompson foundations for generous support of our Alzheimer's disease research.

  • Abbreviations used in this article:

    AD
    Alzheimer's disease
    BCSFB
    blood–cerebrospinal fluid barrier
    CP
    choroid plexus
    TREM2
    triggering receptor expressed on myeloid cells 2.

  • Received July 18, 2019.
  • Accepted November 18, 2019.
  • Copyright © 2020 by The American Association of Immunologists, Inc.

References

  1. ↵
    1. Egan, M. F.,
    2. J. Kost,
    3. P. N. Tariot,
    4. P. S. Aisen,
    5. J. L. Cummings,
    6. B. Vellas,
    7. C. Sur,
    8. Y. Mukai,
    9. T. Voss,
    10. C. Furtek, et al
    . 2018. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 378: 1691–1703.
    OpenUrlCrossRef
    1. Doody, R. S.,
    2. R. Raman,
    3. M. Farlow,
    4. T. Iwatsubo,
    5. B. Vellas,
    6. S. Joffe,
    7. K. Kieburtz,
    8. F. He,
    9. X. Sun,
    10. R. G. Thomas, et al, Alzheimer’s Disease Cooperative Study Steering Committee, Semagacestat Study Group
    . 2013. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N. Engl. J. Med. 369: 341–350.
    OpenUrlCrossRefPubMed
    1. Gauthier, S.,
    2. H. H. Feldman,
    3. L. S. Schneider,
    4. G. K. Wilcock,
    5. G. B. Frisoni,
    6. J. H. Hardlund,
    7. H. J. Moebius,
    8. P. Bentham,
    9. K. A. Kook,
    10. D. J. Wischik, et al
    . 2016. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388: 2873–2884.
    OpenUrl
  2. ↵
    1. Mullard, A.
    2016. Pharma pumps up anti-tau Alzheimer pipeline despite first Phase III failure. Nat. Rev. Drug Discov. 15: 591–592.
    OpenUrl
    1. Masters, C. L.,
    2. R. Bateman,
    3. K. Blennow,
    4. C. C. Rowe,
    5. R. A. Sperling,
    6. J. L. Cummings
    . 2015. Alzheimer’s disease. Nat. Rev. Dis. Primers 1: 15056.
    OpenUrl
  3. ↵
    1. Selkoe, D. J.,
    2. J. Hardy
    . 2016. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8: 595–608.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Panza, F.,
    2. M. Lozupone,
    3. V. Dibello,
    4. A. Greco,
    5. A. Daniele,
    6. D. Seripa,
    7. G. Logroscino,
    8. B. P. Imbimbo
    . 2019. Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer’s disease? Immunotherapy 11: 3–6.
    OpenUrl
  5. ↵
    1. Egan, M. F.,
    2. J. Kost,
    3. T. Voss,
    4. Y. Mukai,
    5. P. S. Aisen,
    6. J. L. Cummings,
    7. P. N. Tariot,
    8. B. Vellas,
    9. C. H. van Dyck,
    10. M. Boada, et al
    . 2019. Randomized trial of verubecestat for prodromal Alzheimer’s disease. N. Engl. J. Med. 380: 1408–1420.
    OpenUrlCrossRef
  6. ↵
    1. Heneka, M. T.,
    2. M. J. Carson,
    3. J. El Khoury,
    4. G. E. Landreth,
    5. F. Brosseron,
    6. D. L. Feinstein,
    7. A. H. Jacobs,
    8. T. Wyss-Coray,
    9. J. Vitorica,
    10. R. M. Ransohoff, et al
    . 2015. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 14: 388–405.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Meyer, P. F.,
    2. J. Tremblay-Mercier,
    3. J. Leoutsakos,
    4. C. Madjar,
    5. M. É. Lafaille-Maignan,
    6. M. Savard,
    7. P. Rosa-Neto,
    8. J. Poirier,
    9. P. Etienne,
    10. J. Breitner, PREVENT-AD Research Group
    . 2019. INTREPAD: a randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. [Published erratum appears in 2019 Neurology 93: 371.] Neurology 92: e2070–e2080.
    OpenUrl
  8. ↵
    1. Wang, J.,
    2. B. J. Gu,
    3. C. L. Masters,
    4. Y. J. Wang
    . 2017. A systemic view of Alzheimer disease - insights from amyloid-β metabolism beyond the brain. [Published erratum appears in 2017 Nat. Rev. Neurol. 13: 703.] Nat. Rev. Neurol. 13: 612–623.
    OpenUrl
    1. Stower, H.
    2018. Searching for Alzheimer’s disease therapies. Nat. Med. 24: 894–897.
    OpenUrlCrossRef
  9. ↵
    1. Verheijen, J.,
    2. K. Sleegers
    . 2018. Understanding Alzheimer disease at the interface between genetics and transcriptomics. Trends Genet. 34: 434–447.
    OpenUrl
  10. ↵
    1. Moalem, G.,
    2. R. Leibowitz-Amit,
    3. E. Yoles,
    4. F. Mor,
    5. I. R. Cohen,
    6. M. Schwartz
    . 1999. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 5: 49–55.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Rapalino, O.,
    2. O. Lazarov-Spiegler,
    3. E. Agranov,
    4. G. J. Velan,
    5. E. Yoles,
    6. M. Fraidakis,
    7. A. Solomon,
    8. R. Gepstein,
    9. A. Katz,
    10. M. Belkin, et al
    . 1998. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat. Med. 4: 814–821.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Hauben, E.,
    2. E. Agranov,
    3. A. Gothilf,
    4. U. Nevo,
    5. A. Cohen,
    6. I. Smirnov,
    7. L. Steinman,
    8. M. Schwartz
    . 2001. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J. Clin. Invest. 108: 591–599.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Kipnis, J.,
    2. H. Cohen,
    3. M. Cardon,
    4. Y. Ziv,
    5. M. Schwartz
    . 2004. T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. [Published erratum appears in 2005 Proc. Natl. Acad. Sci. USA 102: 14122] Proc. Natl. Acad. Sci. USA 101: 8180–8185.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Ziv, Y.,
    2. N. Ron,
    3. O. Butovsky,
    4. G. Landa,
    5. E. Sudai,
    6. N. Greenberg,
    7. H. Cohen,
    8. J. Kipnis,
    9. M. Schwartz
    . 2006. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci. 9: 268–275.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Shechter, R.,
    2. A. London,
    3. C. Varol,
    4. C. Raposo,
    5. M. Cusimano,
    6. G. Yovel,
    7. A. Rolls,
    8. M. Mack,
    9. S. Pluchino,
    10. G. Martino, et al
    . 2009. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med. 6: e1000113.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Shechter, R.,
    2. O. Miller,
    3. G. Yovel,
    4. N. Rosenzweig,
    5. A. London,
    6. J. Ruckh,
    7. K. W. Kim,
    8. E. Klein,
    9. V. Kalchenko,
    10. P. Bendel, et al
    . 2013. Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity 38: 555–569.
    OpenUrlCrossRefPubMed
    1. London, A.,
    2. E. Itskovich,
    3. I. Benhar,
    4. V. Kalchenko,
    5. M. Mack,
    6. S. Jung,
    7. M. Schwartz
    . 2011. Neuroprotection and progenitor cell renewal in the injured adult murine retina requires healing monocyte-derived macrophages. J. Exp. Med. 208: 23–39.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Kunis, G.,
    2. K. Baruch,
    3. N. Rosenzweig,
    4. A. Kertser,
    5. O. Miller,
    6. T. Berkutzki,
    7. M. Schwartz
    . 2013. IFN-γ-dependent activation of the brain’s choroid plexus for CNS immune surveillance and repair. Brain 136: 3427–3440.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Baruch, K.,
    2. N. Rosenzweig,
    3. A. Kertser,
    4. A. Deczkowska,
    5. A. M. Sharif,
    6. A. Spinrad,
    7. A. Tsitsou-Kampeli,
    8. A. Sarel,
    9. L. Cahalon,
    10. M. Schwartz
    . 2015. Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer’s disease pathology. Nat. Commun. 6: 7967.
    OpenUrlCrossRefPubMed
    1. Raposo, C.,
    2. N. Graubardt,
    3. M. Cohen,
    4. C. Eitan,
    5. A. London,
    6. T. Berkutzki,
    7. M. Schwartz
    . 2014. CNS repair requires both effector and regulatory T cells with distinct temporal and spatial profiles. J. Neurosci. 34: 10141–10155.
    OpenUrlAbstract/FREE Full Text
    1. Schwartz, M.,
    2. R. Shechter
    . 2010. Systemic inflammatory cells fight off neurodegenerative disease. Nat. Rev. Neurol. 6: 405–410.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Shechter, R.,
    2. A. London,
    3. M. Schwartz
    . 2013. Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates. Nat. Rev. Immunol. 13: 206–218.
    OpenUrlCrossRefPubMed
    1. Shechter, R.,
    2. M. Schwartz
    . 2013. CNS sterile injury: just another wound healing? Trends Mol. Med. 19: 135–143.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Shechter, R.,
    2. M. Schwartz
    . 2013. Harnessing monocyte-derived macrophages to control central nervous system pathologies: no longer ‘if’ but ‘how’. J. Pathol. 229: 332–346.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Clark, S. M.,
    2. C. N. Vaughn,
    3. J. A. Soroka,
    4. X. Li,
    5. L. H. Tonelli
    . 2018. Neonatal adoptive transfer of lymphocytes rescues social behaviour during adolescence in immune-deficient mice. Eur. J. Neurosci. 47: 968–978.
    OpenUrl
    1. Song, E. J.,
    2. S. G. Jeon,
    3. K. A. Kim,
    4. J. I. Kim,
    5. M. Moon
    . 2017. Restricted CD4+ T cell receptor repertoire impairs cognitive function via alteration of Th2 cytokine levels. Neurogenesis (Austin) 4: e1256856.
    OpenUrl
    1. Qi, F.,
    2. Z. Zuo,
    3. J. Yang,
    4. S. Hu,
    5. Y. Yang,
    6. Q. Yuan,
    7. J. Zou,
    8. K. Guo,
    9. Z. Yao
    . 2017. Combined effect of BCG vaccination and enriched environment promote neurogenesis and spatial cognition via a shift in meningeal macrophage M2 polarization. J. Neuroinflammation 14: 32.
    OpenUrl
    1. Coder, B.,
    2. W. Wang,
    3. L. Wang,
    4. Z. Wu,
    5. Q. Zhuge,
    6. D. M. Su
    . 2017. Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging. Oncotarget 8: 7116–7137.
    OpenUrl
    1. Song, C.,
    2. J. D. Nicholson,
    3. S. M. Clark,
    4. X. Li,
    5. A. D. Keegan,
    6. L. H. Tonelli
    . 2016. Expansion of brain T cells in homeostatic conditions in lymphopenic Rag2(-/-) mice. Brain Behav. Immun. 57: 161–172.
    OpenUrl
  22. ↵
    1. Möhle, L.,
    2. N. Israel,
    3. K. Paarmann,
    4. M. Krohn,
    5. S. Pietkiewicz,
    6. A. Müller,
    7. I. N. Lavrik,
    8. J. S. Buguliskis,
    9. B. H. Schott,
    10. D. Schlüter, et al
    . 2016. Chronic toxoplasma gondii infection enhances β-amyloid phagocytosis and clearance by recruited monocytes. Acta Neuropathol. Commun. 4: 25.
    OpenUrl
  23. ↵
    1. Wattananit, S.,
    2. D. Tornero,
    3. N. Graubardt,
    4. T. Memanishvili,
    5. E. Monni,
    6. J. Tatarishvili,
    7. G. Miskinyte,
    8. R. Ge,
    9. H. Ahlenius,
    10. O. Lindvall, et al
    . 2016. Monocyte-derived macrophages contribute to spontaneous long-term functional recovery after stroke in mice. J. Neurosci. 36: 4182–4195.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Pape, K.,
    2. R. Tamouza,
    3. M. Leboyer,
    4. F. Zipp
    . 2019. Immunoneuropsychiatry - novel perspectives on brain disorders. Nat. Rev. Neurol. 15: 317–328.
    OpenUrl
  25. ↵
    1. Derecki, N. C.,
    2. A. N. Cardani,
    3. C. H. Yang,
    4. K. M. Quinnies,
    5. A. Crihfield,
    6. K. R. Lynch,
    7. J. Kipnis
    . 2010. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J. Exp. Med. 207: 1067–1080.
    OpenUrlAbstract/FREE Full Text
    1. Filiano, A. J.,
    2. S. P. Gadani,
    3. J. Kipnis
    . 2017. How and why do T cells and their derived cytokines affect the injured and healthy brain? Nat. Rev. Neurosci. 18: 375–384.
    OpenUrlCrossRef
  26. ↵
    1. Filiano, A. J.,
    2. Y. Xu,
    3. N. J. Tustison,
    4. R. L. Marsh,
    5. W. Baker,
    6. I. Smirnov,
    7. C. C. Overall,
    8. S. P. Gadani,
    9. S. D. Turner,
    10. Z. Weng, et al
    . 2016. Unexpected role of interferon-γ in regulating neuronal connectivity and social behaviour. Nature 535: 425–429.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Louveau, A.,
    2. B. A. Plog,
    3. S. Antila,
    4. K. Alitalo,
    5. M. Nedergaard,
    6. J. Kipnis
    . 2017. Understanding the functions and relationships of the glymphatic system and meningeal lymphatics. J. Clin. Invest. 127: 3210–3219.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Louveau, A.,
    2. I. Smirnov,
    3. T. J. Keyes,
    4. J. D. Eccles,
    5. S. J. Rouhani,
    6. J. D. Peske,
    7. N. C. Derecki,
    8. D. Castle,
    9. J. W. Mandell,
    10. K. S. Lee, et al
    . 2015. Structural and functional features of central nervous system lymphatic vessels. [Published erratum appears in 2016 Nature 533: 278.] Nature 523: 337–341.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Walsh, J. T.,
    2. S. Hendrix,
    3. F. Boato,
    4. I. Smirnov,
    5. J. Zheng,
    6. J. R. Lukens,
    7. S. Gadani,
    8. D. Hechler,
    9. G. Gölz,
    10. K. Rosenberger, et al
    . 2015. MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4. J. Clin. Invest. 125: 2547.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Baruch, K.,
    2. A. Deczkowska,
    3. E. David,
    4. J. M. Castellano,
    5. O. Miller,
    6. A. Kertser,
    7. T. Berkutzki,
    8. Z. Barnett-Itzhaki,
    9. D. Bezalel,
    10. T. Wyss-Coray, et al
    . 2014. Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346: 89–93.
    OpenUrlAbstract/FREE Full Text
    1. Yousef, H.,
    2. C. J. Czupalla,
    3. D. Lee,
    4. M. B. Chen,
    5. A. N. Burke,
    6. K. A. Zera,
    7. J. Zandstra,
    8. E. Berber,
    9. B. Lehallier,
    10. V. Mathur, et al
    . 2019. Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1. Nat. Med. 25: 988–1000.
    OpenUrl
    1. Matt, S. M.,
    2. R. W. Johnson
    . 2016. Neuro-immune dysfunction during brain aging: new insights in microglial cell regulation. Curr. Opin. Pharmacol. 26: 96–101.
    OpenUrlCrossRefPubMed
    1. Lucin, K. M.,
    2. T. Wyss-Coray
    . 2009. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 64: 110–122.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Villeda, S. A.,
    2. J. Luo,
    3. K. I. Mosher,
    4. B. Zou,
    5. M. Britschgi,
    6. G. Bieri,
    7. T. M. Stan,
    8. N. Fainberg,
    9. Z. Ding,
    10. A. Eggel, et al
    . 2011. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477: 90–94.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Kunis, G.,
    2. K. Baruch,
    3. O. Miller,
    4. M. Schwartz
    . 2015. Immunization with a myelin-derived antigen activates the brain’s choroid plexus for recruitment of immunoregulatory cells to the CNS and attenuates disease progression in a mouse model of ALS. J. Neurosci. 35: 6381–6393.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Mesquita, S. D.,
    2. A. C. Ferreira,
    3. F. Gao,
    4. G. Coppola,
    5. D. H. Geschwind,
    6. J. C. Sousa,
    7. M. Correia-Neves,
    8. N. Sousa,
    9. J. A. Palha,
    10. F. Marques
    . 2015. The choroid plexus transcriptome reveals changes in type I and II interferon responses in a mouse model of Alzheimer’s disease. Brain Behav. Immun. 49: 280–292.
    OpenUrl
  34. ↵
    1. Baruch, K.,
    2. A. Deczkowska,
    3. N. Rosenzweig,
    4. A. Tsitsou-Kampeli,
    5. A. M. Sharif,
    6. O. Matcovitch-Natan,
    7. A. Kertser,
    8. E. David,
    9. I. Amit,
    10. M. Schwartz
    . 2016. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer’s disease. Nat. Med. 22: 135–137.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Rosenzweig, N.,
    2. R. Dvir-Szternfeld,
    3. A. Tsitsou-Kampeli,
    4. H. Keren-Shaul,
    5. H. Ben-Yehuda,
    6. P. Weill-Raynal,
    7. L. Cahalon,
    8. A. Kertser,
    9. K. Baruch,
    10. I. Amit, et al
    . 2019. PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. Nat. Commun. 10: 465.
    OpenUrl
    1. Villeda, S. A.,
    2. K. E. Plambeck,
    3. J. Middeldorp,
    4. J. M. Castellano,
    5. K. I. Mosher,
    6. J. Luo,
    7. L. K. Smith,
    8. G. Bieri,
    9. K. Lin,
    10. D. Berdnik, et al
    . 2014. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat. Med. 20: 659–663.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Wyss-Coray, T.
    2016. Ageing, neurodegeneration and brain rejuvenation. Nature 539: 180–186.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Medawar, P. B.
    1948. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br. J. Exp. Pathol. 29: 58–69.
    OpenUrlPubMed
  38. ↵
    1. Schwartz, M.,
    2. J. Kipnis,
    3. S. Rivest,
    4. A. Prat
    . 2013. How do immune cells support and shape the brain in health, disease, and aging? J. Neurosci. 33: 17587–17596.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Kipnis, J.
    2016. Multifaceted interactions between adaptive immunity and the central nervous system. Science 353: 766–771.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Kipnis, J.,
    2. S. Gadani,
    3. N. C. Derecki
    . 2012. Pro-cognitive properties of T cells. Nat. Rev. Immunol. 12: 663–669.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Radjavi, A.,
    2. I. Smirnov,
    3. N. Derecki,
    4. J. Kipnis
    . 2014. Dynamics of the meningeal CD4(+) T-cell repertoire are defined by the cervical lymph nodes and facilitate cognitive task performance in mice. Mol. Psychiatry 19: 531–533.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Da Mesquita, S.,
    2. A. Louveau,
    3. A. Vaccari,
    4. I. Smirnov,
    5. R. C. Cornelison,
    6. K. M. Kingsmore,
    7. C. Contarino,
    8. S. Onengut-Gumuscu,
    9. E. Farber,
    10. D. Raper, et al
    . 2018. Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease. [Published erratum appears in 2018 Nature 564: E7.] Nature 560: 185–191.
    OpenUrlCrossRefPubMed
    1. Sandrone, S.,
    2. D. Moreno-Zambrano,
    3. J. Kipnis,
    4. J. van Gijn
    . 2019. A (delayed) history of the brain lymphatic system. Nat. Med. 25: 538–540.
    OpenUrl
    1. Antila, S.,
    2. S. Karaman,
    3. H. Nurmi,
    4. M. Airavaara,
    5. M. H. Voutilainen,
    6. T. Mathivet,
    7. D. Chilov,
    8. Z. Li,
    9. T. Koppinen,
    10. J. H. Park, et al
    . 2017. Development and plasticity of meningeal lymphatic vessels. J. Exp. Med. 214: 3645–3667.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Absinta, M.,
    2. S. K. Ha,
    3. G. Nair,
    4. P. Sati,
    5. N. J. Luciano,
    6. M. Palisoc,
    7. A. Louveau,
    8. K. A. Zaghloul,
    9. S. Pittaluga,
    10. J. Kipnis,
    11. D. S. Reich
    . 2017. Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI. eLife 6: e29738.
    OpenUrl
  44. ↵
    1. Vargas, M. E.,
    2. B. A. Barres
    . 2007. Why is Wallerian degeneration in the CNS so slow? Annu. Rev. Neurosci. 30: 153–179.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Perry, V. H.,
    2. P. B. Andersson,
    3. S. Gordon
    . 1993. Macrophages and inflammation in the central nervous system. Trends Neurosci. 16: 268–273.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Buckley, C. D.,
    2. D. W. Gilroy,
    3. C. N. Serhan,
    4. B. Stockinger,
    5. P. P. Tak
    . 2013. The resolution of inflammation. Nat. Rev. Immunol. 13: 59–66.
    OpenUrlCrossRefPubMed
    1. Gronert, K.
    2010. Resolution, the grail for healthy ocular inflammation. Exp. Eye Res. 91: 478–485.
    OpenUrlCrossRefPubMed
  47. ↵
    1. London, A.,
    2. I. Benhar,
    3. M. J. Mattapallil,
    4. M. Mack,
    5. R. R. Caspi,
    6. M. Schwartz
    . 2013. Functional macrophage heterogeneity in a mouse model of autoimmune central nervous system pathology. J. Immunol. 190: 3570–3578.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Schwartz, M.,
    2. K. Baruch
    . 2014. The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J. 33: 7–22.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Mills, C. D.,
    2. K. Ley
    . 2014. M1 and M2 macrophages: the chicken and the egg of immunity. J. Innate Immun. 6: 716–726.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Popovich, P. G.,
    2. T. B. Jones
    . 2003. Manipulating neuroinflammatory reactions in the injured spinal cord: back to basics. Trends Pharmacol. Sci. 24: 13–17.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Young, W.
    2002. Methylprednisolone and spinal cord injury. J. Neurosurg. 96(1 Suppl.): 141–142.
    OpenUrlPubMed
  52. ↵
    1. Trivedi, A.,
    2. A. D. Olivas,
    3. L. J. Noble-Haeusslein
    . 2006. Inflammation and spinal cord injury: infiltrating leukocytes as determinants of injury and repair processes. Clin. Neurosci. Res. 6: 283–292.
    OpenUrlCrossRefPubMed
  53. ↵
    1. Tran, A. P.,
    2. P. M. Warren,
    3. J. Silver
    . 2018. The biology of regeneration failure and success after spinal cord injury. Physiol. Rev. 98: 881–917.
    OpenUrlCrossRefPubMed
  54. ↵
    1. Fan, L. W.,
    2. Y. Pang
    . 2017. Dysregulation of neurogenesis by neuroinflammation: key differences in neurodevelopmental and neurological disorders. Neural Regen. Res. 12: 366–371.
    OpenUrl
    1. Ekdahl, C. T.,
    2. J. H. Claasen,
    3. S. Bonde,
    4. Z. Kokaia,
    5. O. Lindvall
    . 2003. Inflammation is detrimental for neurogenesis in adult brain. Proc. Natl. Acad. Sci. USA 100: 13632–13637.
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Monje, M. L.,
    2. H. Toda,
    3. T. D. Palmer
    . 2003. Inflammatory blockade restores adult hippocampal neurogenesis. Science 302: 1760–1765.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Bracken, M. B.,
    2. M. J. Shepard,
    3. W. F. Collins,
    4. T. R. Holford,
    5. W. Young,
    6. D. S. Baskin,
    7. H. M. Eisenberg,
    8. E. Flamm,
    9. L. Leo-Summers,
    10. J. Maroon, et al
    . 1990. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the second national acute spinal cord injury study. N. Engl. J. Med. 322: 1405–1411.
    OpenUrlCrossRefPubMed
  57. ↵
    1. Yin, Y.,
    2. M. T. Henzl,
    3. B. Lorber,
    4. T. Nakazawa,
    5. T. T. Thomas,
    6. F. Jiang,
    7. R. Langer,
    8. L. I. Benowitz
    . 2006. Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells. Nat. Neurosci. 9: 843–852.
    OpenUrlCrossRefPubMed
  58. ↵
    1. Kigerl, K. A.,
    2. J. C. Gensel,
    3. D. P. Ankeny,
    4. J. K. Alexander,
    5. D. J. Donnelly,
    6. P. G. Popovich
    . 2009. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J. Neurosci. 29: 13435–13444.
    OpenUrlAbstract/FREE Full Text
    1. Ishii, H.,
    2. X. Jin,
    3. M. Ueno,
    4. S. Tanabe,
    5. T. Kubo,
    6. S. Serada,
    7. T. Naka,
    8. T. Yamashita
    . 2012. Adoptive transfer of Th1-conditioned lymphocytes promotes axonal remodeling and functional recovery after spinal cord injury. Cell Death Dis. 3: e363.
    OpenUrlCrossRefPubMed
    1. Greenhalgh, A. D.,
    2. S. David
    . 2014. Differences in the phagocytic response of microglia and peripheral macrophages after spinal cord injury and its effects on cell death. J. Neurosci. 34: 6316–6322.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    1. Cusimano, M.,
    2. D. Biziato,
    3. E. Brambilla,
    4. M. Donegà,
    5. C. Alfaro-Cervello,
    6. S. Snider,
    7. G. Salani,
    8. F. Pucci,
    9. G. Comi,
    10. J. M. Garcia-Verdugo, et al
    . 2012. Transplanted neural stem/precursor cells instruct phagocytes and reduce secondary tissue damage in the injured spinal cord. Brain 135: 447–460.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Butovsky, O.,
    2. M. Koronyo-Hamaoui,
    3. G. Kunis,
    4. E. Ophir,
    5. G. Landa,
    6. H. Cohen,
    7. M. Schwartz
    . 2006. Glatiramer acetate fights against Alzheimer’s disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc. Natl. Acad. Sci. USA 103: 11784–11789.
    OpenUrlAbstract/FREE Full Text
    1. Butovsky, O.,
    2. G. Kunis,
    3. M. Koronyo-Hamaoui,
    4. M. Schwartz
    . 2007. Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer’s disease model. Eur. J. Neurosci. 26: 413–416.
    OpenUrlCrossRefPubMed
  61. ↵
    1. Simard, A. R.,
    2. D. Soulet,
    3. G. Gowing,
    4. J. P. Julien,
    5. S. Rivest
    . 2006. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer’s disease. Neuron 49: 489–502.
    OpenUrlCrossRefPubMed
  62. ↵
    1. Naert, G.,
    2. S. Rivest
    . 2013. A deficiency in CCR2+ monocytes: the hidden side of Alzheimer’s disease. J. Mol. Cell Biol. 5: 284–293.
    OpenUrlCrossRefPubMed
  63. ↵
    1. Town, T.,
    2. Y. Laouar,
    3. C. Pittenger,
    4. T. Mori,
    5. C. A. Szekely,
    6. J. Tan,
    7. R. S. Duman,
    8. R. A. Flavell
    . 2008. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 14: 681–687.
    OpenUrlCrossRefPubMed
    1. Koronyo-Hamaoui, M.,
    2. M. K. Ko,
    3. Y. Koronyo,
    4. D. Azoulay,
    5. A. Seksenyan,
    6. G. Kunis,
    7. M. Pham,
    8. J. Bakhsheshian,
    9. P. Rogeri,
    10. K. L. Black, et al
    . 2009. Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. J. Neurochem. 111: 1409–1424.
    OpenUrlCrossRefPubMed
  64. ↵
    1. Koronyo, Y.,
    2. B. C. Salumbides,
    3. J. Sheyn,
    4. L. Pelissier,
    5. S. Li,
    6. V. Ljubimov,
    7. M. Moyseyev,
    8. D. Daley,
    9. D. T. Fuchs,
    10. M. Pham, et al
    . 2015. Therapeutic effects of glatiramer acetate and grafted CD115+ monocytes in a mouse model of Alzheimer’s disease. Brain 138: 2399–2422.
    OpenUrlCrossRefPubMed
  65. ↵
    1. El Khoury, J.,
    2. M. Toft,
    3. S. E. Hickman,
    4. T. K. Means,
    5. K. Terada,
    6. C. Geula,
    7. A. D. Luster
    . 2007. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 13: 432–438.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Beers, D. R.,
    2. J. S. Henkel,
    3. W. Zhao,
    4. J. Wang,
    5. S. H. Appel
    . 2008. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. USA 105: 15558–15563.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    1. Henkel, J. S.,
    2. D. R. Beers,
    3. S. Wen,
    4. A. L. Rivera,
    5. K. M. Toennis,
    6. J. E. Appel,
    7. W. Zhao,
    8. D. H. Moore,
    9. S. Z. Powell,
    10. S. H. Appel
    . 2013. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. [Published erratum appears in 2013 EMBO Mol. Med. 5: 326.] EMBO Mol. Med. 5: 64–79.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Rolls, A.,
    2. R. Shechter,
    3. A. London,
    4. Y. Segev,
    5. J. Jacob-Hirsch,
    6. N. Amariglio,
    7. G. Rechavi,
    8. M. Schwartz
    . 2008. Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in microglia/macrophage activation. PLoS Med. 5: e171.
    OpenUrlCrossRefPubMed
  69. ↵
    1. Shechter, R.,
    2. C. Raposo,
    3. A. London,
    4. I. Sagi,
    5. M. Schwartz
    . 2011. The glial scar-monocyte interplay: a pivotal resolution phase in spinal cord repair. PLoS One 6: e27969.
    OpenUrlCrossRefPubMed
  70. ↵
    1. Yao, J.,
    2. Y. Mu,
    3. F. H. Gage
    . 2012. Neural stem cells: mechanisms and modeling. [Published erratum appears in 2012 Protein Cell 3: 559.] Protein Cell 3: 251–261.
    OpenUrlCrossRefPubMed
  71. ↵
    1. van Praag, H.,
    2. A. F. Schinder,
    3. B. R. Christie,
    4. N. Toni,
    5. T. D. Palmer,
    6. F. H. Gage
    . 2002. Functional neurogenesis in the adult hippocampus. Nature 415: 1030–1034.
    OpenUrlCrossRefPubMed
  72. ↵
    1. Santarelli, L.,
    2. M. Saxe,
    3. C. Gross,
    4. A. Surget,
    5. F. Battaglia,
    6. S. Dulawa,
    7. N. Weisstaub,
    8. J. Lee,
    9. R. Duman,
    10. O. Arancio, et al
    . 2003. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301: 805–809.
    OpenUrlAbstract/FREE Full Text
  73. ↵
    1. Abrous, D. N.,
    2. J. M. Wojtowicz
    . 2015. Interaction between neurogenesis and hippocampal memory system: new vistas. Cold Spring Harb. Perspect. Biol. 7: a018952.
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Brynskikh, A.,
    2. T. Warren,
    3. J. Zhu,
    4. J. Kipnis
    . 2008. Adaptive immunity affects learning behavior in mice. Brain Behav. Immun. 22: 861–869.
    OpenUrlCrossRefPubMed
  75. ↵
    1. Kokaia, Z.,
    2. G. Martino,
    3. M. Schwartz,
    4. O. Lindvall
    . 2012. Cross-talk between neural stem cells and immune cells: the key to better brain repair? Nat. Neurosci. 15: 1078–1087.
    OpenUrlCrossRefPubMed
  76. ↵
    Kertser, A., K. Baruch, A. Deczkowska, A. Weiner, T. Croese, M. Kenigsbuch, I. Cooper, M. Tsoory, S. Ben-Hamo, I. Amit, and M. Schwartz. 2019. Corticosteroid signaling at the brain-immune interface impedes coping with severe psychological stress. Sci. Adv. 5: eaav4111
    1. Cohen, H.,
    2. Y. Ziv,
    3. M. Cardon,
    4. Z. Kaplan,
    5. M. A. Matar,
    6. Y. Gidron,
    7. M. Schwartz,
    8. J. Kipnis
    . 2006. Maladaptation to mental stress mitigated by the adaptive immune system via depletion of naturally occurring regulatory CD4+CD25+ cells. J. Neurobiol. 66: 552–563.
    OpenUrlCrossRefPubMed
  77. ↵
    1. Lewitus, G. M.,
    2. H. Cohen,
    3. M. Schwartz
    . 2008. Reducing post-traumatic anxiety by immunization. Brain Behav. Immun. 22: 1108–1114.
    OpenUrlCrossRefPubMed
  78. ↵
    1. Warren, R. P.,
    2. L. J. Yonk,
    3. R. A. Burger,
    4. P. Cole,
    5. J. D. Odell,
    6. W. L. Warren,
    7. E. White,
    8. V. K. Singh
    . 1990. Deficiency of suppressor-inducer (CD4+CD45RA+) T cells in autism. Immunol. Invest. 19: 245–251.
    OpenUrlPubMed
    1. Yonk, L. J.,
    2. R. P. Warren,
    3. R. A. Burger,
    4. P. Cole,
    5. J. D. Odell,
    6. W. L. Warren,
    7. E. White,
    8. V. K. Singh
    . 1990. CD4+ helper T cell depression in autism. Immunol. Lett. 25: 341–345.
    OpenUrlCrossRefPubMed
    1. Ashwood, P.,
    2. P. Krakowiak,
    3. I. Hertz-Picciotto,
    4. R. Hansen,
    5. I. N. Pessah,
    6. J. Van de Water
    . 2011. Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders. J. Neuroimmunol. 232: 196–199.
    OpenUrlCrossRefPubMed
  79. ↵
    1. Filiano, A. J.,
    2. S. P. Gadani,
    3. J. Kipnis
    . 2015. Interactions of innate and adaptive immunity in brain development and function. Brain Res. 1617: 18–27.
    OpenUrl
  80. ↵
    1. Bartholomäus, I.,
    2. N. Kawakami,
    3. F. Odoardi,
    4. C. Schläger,
    5. D. Miljkovic,
    6. J. W. Ellwart,
    7. W. E. Klinkert,
    8. C. Flügel-Koch,
    9. T. B. Issekutz,
    10. H. Wekerle,
    11. A. Flügel
    . 2009. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 462: 94–98.
    OpenUrlCrossRefPubMed
  81. ↵
    1. Reboldi, A.,
    2. C. Coisne,
    3. D. Baumjohann,
    4. F. Benvenuto,
    5. D. Bottinelli,
    6. S. Lira,
    7. A. Uccelli,
    8. A. Lanzavecchia,
    9. B. Engelhardt,
    10. F. Sallusto
    . 2009. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 10: 514–523.
    OpenUrlCrossRefPubMed
  82. ↵
    1. Silva-Vargas, V.,
    2. A. R. Maldonado-Soto,
    3. D. Mizrak,
    4. P. Codega,
    5. F. Doetsch
    . 2016. Age-dependent niche signals from the choroid plexus regulate adult neural stem cells. Cell Stem Cell 19: 643–652.
    OpenUrlCrossRefPubMed
    1. Emerich, D. F.,
    2. S. J. Skinner,
    3. C. V. Borlongan,
    4. A. V. Vasconcellos,
    5. C. G. Thanos
    . 2005. The choroid plexus in the rise, fall and repair of the brain. Bioessays 27: 262–274.
    OpenUrlCrossRefPubMed
    1. Redzic, Z.
    2011. Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS 8: 3.
    OpenUrlCrossRefPubMed
    1. Meeker, R. B.,
    2. K. Williams,
    3. D. A. Killebrew,
    4. L. C. Hudson
    . 2012. Cell trafficking through the choroid plexus. Cell Adh. Migr. 6: 390–396.
    OpenUrlCrossRefPubMed
  83. ↵
    1. Korin, B.,
    2. T. L. Ben-Shaanan,
    3. M. Schiller,
    4. T. Dubovik,
    5. H. Azulay-Debby,
    6. N. T. Boshnak,
    7. T. Koren,
    8. A. Rolls
    . 2017. High-dimensional, single-cell characterization of the brain’s immune compartment. Nat. Neurosci. 20: 1300–1309.
    OpenUrlCrossRefPubMed
  84. ↵
    1. Ginhoux, F.,
    2. M. Prinz
    . 2015. Origin of microglia: current concepts and past controversies. Cold Spring Harb. Perspect. Biol. 7: a020537.
    OpenUrlAbstract/FREE Full Text
    1. Wolf, S. A.,
    2. H. W. Boddeke,
    3. H. Kettenmann
    . 2017. Microglia in physiology and disease. Annu. Rev. Physiol. 79: 619–643.
    OpenUrlCrossRefPubMed
  85. ↵
    1. Streit, W. J.,
    2. M. B. Graeber,
    3. G. W. Kreutzberg
    . 1988. Functional plasticity of microglia: a review. Glia 1: 301–307.
    OpenUrlCrossRefPubMed
  86. ↵
    1. Deczkowska, A.,
    2. I. Amit,
    3. M. Schwartz
    . 2018. Microglial immune checkpoint mechanisms. [Published erratum appears in 2018 Nat. Neurosci. 21: 1137.] Nat. Neurosci. 21: 779–786.
    OpenUrl
  87. ↵
    1. Cohen, M.,
    2. O. Matcovitch,
    3. E. David,
    4. Z. Barnett-Itzhaki,
    5. H. Keren-Shaul,
    6. R. Blecher-Gonen,
    7. D. A. Jaitin,
    8. A. Sica,
    9. I. Amit,
    10. M. Schwartz
    . 2014. Chronic exposure to TGFβ1 regulates myeloid cell inflammatory response in an IRF7-dependent manner. EMBO J. 33: 2906–2921.
    OpenUrlAbstract/FREE Full Text
  88. ↵
    1. Xie, X.,
    2. X. Luo,
    3. N. Liu,
    4. X. Li,
    5. F. Lou,
    6. Y. Zheng,
    7. Y. Ren
    . 2017. Monocytes, microglia, and CD200-CD200R1 signaling are essential in the transmission of inflammation from the periphery to the central nervous system. J. Neurochem. 141: 222–235.
    OpenUrl
  89. ↵
    Eyo, U. B., J. Peng, M. Murugan, M. Mo, A. Lalani, P. Xie, P. Xu, D. J. Margolis, and L. J. Wu. 2017. Regulation of physical microglia-neuron interactions by fractalkine signaling after status epilepticus. eNeuro. DOI: 10.1523/ENEURO.0209-16.2016.
  90. ↵
    1. Butovsky, O.,
    2. M. P. Jedrychowski,
    3. C. S. Moore,
    4. R. Cialic,
    5. A. J. Lanser,
    6. G. Gabriely,
    7. T. Koeglsperger,
    8. B. Dake,
    9. P. M. Wu,
    10. C. E. Doykan, et al
    . 2014. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. [Published erratum appears in 2014 Nat. Neurosci. 17: 1286.] Nat. Neurosci. 17: 131–143.
    OpenUrlCrossRefPubMed
  91. ↵
    1. Kierdorf, K.,
    2. M. Prinz
    . 2013. Factors regulating microglia activation. Front. Cell. Neurosci. 7: 44.
    OpenUrlCrossRefPubMed
  92. ↵
    Keren-Shaul, H., A. Spinrad, A. Weiner, O. Matcovitch-Natan, R. Dvir-Szternfeld, T. K. Ulland, E. David, K. Baruch, D. Lara-Astaiso, B. Toth, et al. 2017. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169: 1276–1290.e17.
  93. Sala Frigerio, C., L. Wolfs, N. Fattorelli, N. Thrupp, I. Voytyuk, I. Schmidt, R. Mancuso, W. T. Chen, M. E. Woodbury, G. Srivastava, et al. 2019. The major risk factors for Alzheimer’s disease: age, sex, and genes modulate the microglia response to Aβ plaques. Cell Rep. 27: 1293–1306.e6.
    1. Masuda, T.,
    2. R. Sankowski,
    3. O. Staszewski,
    4. C. Böttcher,
    5. L. Amann
    6. Sagar
    7. C. Scheiwe,
    8. S. Nessler,
    9. P. Kunz,
    10. G. van Loo, et al
    . 2019. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. [Published erratum appears in 2019 Nature 568: E4.] Nature 566: 388–392.
    OpenUrlCrossRef
  94. ↵
    1. Böttcher, C.,
    2. S. Schlickeiser,
    3. M. A. M. Sneeboer,
    4. D. Kunkel,
    5. A. Knop,
    6. E. Paza,
    7. P. Fidzinski,
    8. L. Kraus,
    9. G. J. L. Snijders,
    10. R. S. Kahn, et al, NBB-Psy
    . 2019. Human microglia regional heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry. Nat. Neurosci. 22: 78–90.
    OpenUrlCrossRef
  95. ↵
    1. Ajami, B.,
    2. N. Samusik,
    3. P. Wieghofer,
    4. P. P. Ho,
    5. A. Crotti,
    6. Z. Bjornson,
    7. M. Prinz,
    8. W. J. Fantl,
    9. G. P. Nolan,
    10. L. Steinman
    . 2018. Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models. Nat. Neurosci. 21: 541–551.
    OpenUrlCrossRefPubMed
  96. Mrdjen, D., A. Pavlovic, F. J. Hartmann, B. Schreiner, S. G. Utz, B. P. Leung, I. Lelios, F. L. Heppner, J. Kipnis, D. Merkler, et al. 2018. High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. [Published erratum appears in 2018 Immunity 48: 599.] Immunity 48: 380–395.e6.
  97. Jordão, M. J. C., R. Sankowski, S. M. Brendecke, Sagar, G. Locatelli, Y. H. Tai, T. L. Tay, E. Schramm, S. Armbruster, N. Hagemeyer, et al. 2019. Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. Science 363: eaat7554.
  98. ↵
    1. Van Hove, H.,
    2. L. Martens,
    3. I. Scheyltjens,
    4. K. De Vlaminck,
    5. A. R. Pombo Antunes,
    6. S. De Prijck,
    7. N. Vandamme,
    8. S. De Schepper,
    9. G. Van Isterdael,
    10. C. L. Scott, et al
    . 2019. A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat. Neurosci. 22: 1021–1035.
    OpenUrlCrossRef
  99. ↵
    1. Guerreiro, R.,
    2. A. Wojtas,
    3. J. Bras,
    4. M. Carrasquillo,
    5. E. Rogaeva,
    6. E. Majounie,
    7. C. Cruchaga,
    8. C. Sassi,
    9. J. S. Kauwe,
    10. S. Younkin, et al, Alzheimer Genetic Analysis Group
    . 2013. TREM2 variants in Alzheimer’s disease. N. Engl. J. Med. 368: 117–127.
    OpenUrlCrossRefPubMed
    1. Jonsson, T.,
    2. H. Stefansson,
    3. S. Steinberg,
    4. I. Jonsdottir,
    5. P. V. Jonsson,
    6. J. Snaedal,
    7. S. Bjornsson,
    8. J. Huttenlocher,
    9. A. I. Levey,
    10. J. J. Lah, et al
    . 2013. Variant of TREM2 associated with the risk of Alzheimer’s disease. N. Engl. J. Med. 368: 107–116.
    OpenUrlCrossRefPubMed
    1. Kleinberger, G.,
    2. Y. Yamanishi,
    3. M. Suárez-Calvet,
    4. E. Czirr,
    5. E. Lohmann,
    6. E. Cuyvers,
    7. H. Struyfs,
    8. N. Pettkus,
    9. A. Wenninger-Weinzierl,
    10. F. Mazaheri, et al
    . 2014. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med. 6: 243ra86.
    OpenUrlAbstract/FREE Full Text
  100. ↵
    1. Jay, T. R.,
    2. C. M. Miller,
    3. P. J. Cheng,
    4. L. C. Graham,
    5. S. Bemiller,
    6. M. L. Broihier,
    7. G. Xu,
    8. D. Margevicius,
    9. J. C. Karlo,
    10. G. L. Sousa, et al
    . 2015. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J. Exp. Med. 212: 287–295.
    OpenUrlAbstract/FREE Full Text
  101. ↵
    1. Deczkowska, A.,
    2. H. Keren-Shaul,
    3. A. Weiner,
    4. M. Colonna,
    5. M. Schwartz,
    6. I. Amit
    . 2018. Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell 173: 1073–1081.
    OpenUrlCrossRefPubMed
  102. ↵
    1. Norris, G. T.,
    2. J. Kipnis
    . 2019. Immune cells and CNS physiology: microglia and beyond. J. Exp. Med. 216: 60–70.
    OpenUrlAbstract/FREE Full Text
  103. ↵
    1. Carmona, S.,
    2. K. Zahs,
    3. E. Wu,
    4. K. Dakin,
    5. J. Bras,
    6. R. Guerreiro
    . 2018. The role of TREM2 in Alzheimer’s disease and other neurodegenerative disorders. Lancet Neurol. 17: 721–730.
    OpenUrlCrossRef
  104. Krasemann, S., C. Madore, R. Cialic, C. Baufeld, N. Calcagno, R. El Fatimy, L. Beckers, E. O’Loughlin, Y. Xu, Z. Fanek, et al. 2017. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47: 566–581.e9.
    1. Konishi, H.,
    2. H. Kiyama
    . 2018. Microglial TREM2/DAP12 signaling: a double-edged sword in neural diseases. Front. Cell. Neurosci. 12: 206.
    OpenUrl
    1. Leyns, C. E. G.,
    2. J. D. Ulrich,
    3. M. B. Finn,
    4. F. R. Stewart,
    5. L. J. Koscal,
    6. J. Remolina Serrano,
    7. G. O. Robinson,
    8. E. Anderson,
    9. M. Colonna,
    10. D. M. Holtzman
    . 2017. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc. Natl. Acad. Sci. USA 114: 11524–11529.
    OpenUrlAbstract/FREE Full Text
    1. Jay, T. R.,
    2. A. M. Hirsch,
    3. M. L. Broihier,
    4. C. M. Miller,
    5. L. E. Neilson,
    6. R. M. Ransohoff,
    7. B. T. Lamb,
    8. G. E. Landreth
    . 2017. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer’s disease. J. Neurosci. 37: 637–647.
    OpenUrlAbstract/FREE Full Text
  105. ↵
    1. Deming, Y.,
    2. Z. Li,
    3. B. A. Benitez,
    4. C. Cruchaga
    . 2018. Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease? Expert Opin. Ther. Targets 22: 587–598.
    OpenUrl
  106. ↵
    1. Simard, A. R.,
    2. S. Rivest
    . 2006. Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer’s disease. Mol. Psychiatry 11: 327–335.
    OpenUrlCrossRefPubMed
    1. Boissonneault, V.,
    2. M. Filali,
    3. M. Lessard,
    4. J. Relton,
    5. G. Wong,
    6. S. Rivest
    . 2009. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer’s disease. Brain 132: 1078–1092.
    OpenUrlCrossRefPubMed
  107. ↵
    1. Thériault, P.,
    2. A. ElAli,
    3. S. Rivest
    . 2015. The dynamics of monocytes and microglia in Alzheimer’s disease. Alzheimers Res. Ther. 7: 41.
    OpenUrlCrossRefPubMed
    1. Herz, J.,
    2. A. J. Filiano,
    3. A. Smith,
    4. N. Yogev,
    5. J. Kipnis
    . 2017. Myeloid cells in the central nervous system. Immunity 46: 943–956.
    OpenUrl
  108. ↵
    1. Li, Q.,
    2. B. A. Barres
    . 2018. Microglia and macrophages in brain homeostasis and disease. Nat. Rev. Immunol. 18: 225–242.
    OpenUrlCrossRefPubMed
  109. ↵
    1. Lampron, A.,
    2. P. M. Pimentel-Coelho,
    3. S. Rivest
    . 2013. Migration of bone marrow-derived cells into the central nervous system in models of neurodegeneration. J. Comp. Neurol. 521: 3863–3876.
    OpenUrlCrossRefPubMed
  110. ↵
    1. Hjorth, E.,
    2. M. Zhu,
    3. V. C. Toro,
    4. I. Vedin,
    5. J. Palmblad,
    6. T. Cederholm,
    7. Y. Freund-Levi,
    8. G. Faxen-Irving,
    9. L. O. Wahlund,
    10. H. Basun, et al
    . 2013. Omega-3 fatty acids enhance phagocytosis of Alzheimer’s disease-related amyloid-β42 by human microglia and decrease inflammatory markers. J. Alzheimers Dis. 35: 697–713.
    OpenUrlCrossRefPubMed
  111. ↵
    1. Yu, Y.,
    2. Q. Shen,
    3. Y. Lai,
    4. S. Y. Park,
    5. X. Ou,
    6. D. Lin,
    7. M. Jin,
    8. W. Zhang
    . 2018. Anti-inflammatory effects of curcumin in microglial cells. Front. Pharmacol. 9: 386.
    OpenUrl
  112. ↵
    1. Lue, L. F.,
    2. Y. M. Kuo,
    3. T. Beach,
    4. D. G. Walker
    . 2010. Microglia activation and anti-inflammatory regulation in Alzheimer’s disease. Mol. Neurobiol. 41: 115–128.
    OpenUrlCrossRefPubMed
  113. ↵
    1. Moussa, C.,
    2. M. Hebron,
    3. X. Huang,
    4. J. Ahn,
    5. R. A. Rissman,
    6. P. S. Aisen,
    7. R. S. Turner
    . 2017. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. J. Neuroinflammation 14: 1.
    OpenUrlCrossRefPubMed
  114. ↵
    1. Karran, E.,
    2. M. Mercken,
    3. B. De Strooper
    . 2011. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10: 698–712.
    OpenUrlCrossRefPubMed
    1. Castello, M. A.,
    2. S. Soriano
    . 2014. On the origin of Alzheimer’s disease. Trials and tribulations of the amyloid hypothesis. Ageing Res. Rev. 13: 10–12.
    OpenUrl
  115. ↵
    1. Selkoe, D.
    2019. β-secretase inhibitors for Alzheimer’s disease: heading in the wrong direction? Lancet Neurol. 18: 624–626.
    OpenUrl
  116. ↵
    1. Ricciarelli, R.,
    2. E. Fedele
    . 2017. The amyloid cascade hypothesis in Alzheimer’s disease: it’s time to change our mind. Curr. Neuropharmacol. 15: 926–935.
    OpenUrl
    1. Dong, Y.,
    2. X. Li,
    3. J. Cheng,
    4. L. Hou
    . 2019. Drug development for Alzheimer’s disease: microglia induced neuroinflammation as a target? Int. J. Mol. Sci. 20: E558.
    OpenUrl
  117. ↵
    1. Mathys, H.,
    2. J. Davila-Velderrain,
    3. Z. Peng,
    4. F. Gao,
    5. S. Mohammadi,
    6. J. Z. Young,
    7. M. Menon,
    8. L. He,
    9. F. Abdurrob,
    10. X. Jiang, et al
    . 2019. Single-cell transcriptomic analysis of Alzheimer’s disease. [Published erratum appears in 2019 Nature 571: E1.] Nature 570: 332–337.
    OpenUrl
  118. ↵
    1. Marsh, S. E.,
    2. E. M. Abud,
    3. A. Lakatos,
    4. A. Karimzadeh,
    5. S. T. Yeung,
    6. H. Davtyan,
    7. G. M. Fote,
    8. L. Lau,
    9. J. G. Weinger,
    10. T. E. Lane, et al
    . 2016. The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function. Proc. Natl. Acad. Sci. USA 113: E1316–E1325.
    OpenUrlAbstract/FREE Full Text
    1. Appel, S. H.,
    2. D. R. Beers,
    3. J. S. Henkel
    . 2010. T cell-microglial dialogue in Parkinson’s disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol. 31: 7–17.
    OpenUrlCrossRefPubMed
    1. Monsonego, A.,
    2. A. Nemirovsky,
    3. I. Harpaz
    . 2013. CD4 T cells in immunity and immunotherapy of Alzheimer’s disease. Immunology 139: 438–446.
    OpenUrl
  119. ↵
    1. Liu, J.,
    2. Y. Ma,
    3. S. Tian,
    4. L. Zhang,
    5. M. Zhao,
    6. Y. Zhang,
    7. D. Xu
    . 2014. T cells promote the regeneration of neural precursor cells in the hippocampus of Alzheimer’s disease mice. Neural Regen. Res. 9: 1541–1547.
    OpenUrl
  120. ↵
    1. Pardoll, D. M.
    2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12: 252–264.
    OpenUrlCrossRefPubMed
  121. ↵
    1. Beers, D. R.,
    2. J. S. Henkel,
    3. W. Zhao,
    4. J. Wang,
    5. A. Huang,
    6. S. Wen,
    7. B. Liao,
    8. S. H. Appel
    . 2011. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 134: 1293–1314.
    OpenUrlCrossRefPubMed
  122. ↵
    1. Pluvinage, J. V.,
    2. M. S. Haney,
    3. B. A. H. Smith,
    4. J. Sun,
    5. T. Iram,
    6. L. Bonanno,
    7. L. Li,
    8. D. P. Lee,
    9. D. W. Morgens,
    10. A. C. Yang, et al
    . 2019. CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. Nature 568: 187–192.
    OpenUrlCrossRef
  123. ↵
    1. Griciuc, A.,
    2. A. Serrano-Pozo,
    3. A. R. Parrado,
    4. A. N. Lesinski,
    5. C. N. Asselin,
    6. K. Mullin,
    7. B. Hooli,
    8. S. H. Choi,
    9. B. T. Hyman,
    10. R. E. Tanzi
    . 2013. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78: 631–643.
    OpenUrlCrossRefPubMed
  124. ↵
    1. Schlepckow, K.,
    2. G. Kleinberger,
    3. A. Fukumori,
    4. R. Feederle,
    5. S. F. Lichtenthaler,
    6. H. Steiner,
    7. C. Haass
    . 2017. An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. EMBO Mol. Med. 9: 1356–1365.
    OpenUrlAbstract/FREE Full Text
  125. ↵
    1. Schwartz, M.
    2017. Can immunotherapy treat neurodegeneration? Science 357: 254–255.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Immunology: 204 (2)
The Journal of Immunology
Vol. 204, Issue 2
15 Jan 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A 20-Year Journey from Axonal Injury to Neurodegenerative Diseases and the Prospect of Immunotherapy for Combating Alzheimer’s Disease
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A 20-Year Journey from Axonal Injury to Neurodegenerative Diseases and the Prospect of Immunotherapy for Combating Alzheimer’s Disease
Michal Schwartz, Javier M. Peralta Ramos, Hila Ben-Yehuda
The Journal of Immunology January 15, 2020, 204 (2) 243-250; DOI: 10.4049/jimmunol.1900844

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A 20-Year Journey from Axonal Injury to Neurodegenerative Diseases and the Prospect of Immunotherapy for Combating Alzheimer’s Disease
Michal Schwartz, Javier M. Peralta Ramos, Hila Ben-Yehuda
The Journal of Immunology January 15, 2020, 204 (2) 243-250; DOI: 10.4049/jimmunol.1900844
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Introduction
    • Peripheral immune cell involvement in recovery from acute CNS injury
    • Peripheral immune cells in CNS homeostasis
    • Neurodegenerative diseases and myeloid cells
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Translating JAKs to Jakinibs
  • Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases
Show more TRANSLATING IMMUNOLOGY

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • Public Access
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2021 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606